Hanson & Doremus Investment Management grew its position in shares of Pfizer Inc. (NYSE:PFE) by 3.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 130,970 shares of the biopharmaceutical company’s stock after acquiring an additional 4,036 shares during the quarter. Pfizer accounts for approximately 1.6% of Hanson & Doremus Investment Management’s portfolio, making the stock its 8th largest holding. Hanson & Doremus Investment Management’s holdings in Pfizer were worth $4,676,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in Pfizer by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after acquiring an additional 9,239,499 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Pfizer by 0.9% during the 2nd quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock worth $1,550,754,000 after acquiring an additional 389,629 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Pfizer by 4.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock worth $1,487,617,000 after acquiring an additional 2,028,313 shares during the last quarter. Fisher Asset Management LLC boosted its holdings in Pfizer by 3.2% during the 3rd quarter. Fisher Asset Management LLC now owns 35,120,799 shares of the biopharmaceutical company’s stock worth $1,253,813,000 after acquiring an additional 1,085,437 shares during the last quarter. Finally, LSV Asset Management boosted its holdings in Pfizer by 0.6% during the 2nd quarter. LSV Asset Management now owns 33,275,572 shares of the biopharmaceutical company’s stock worth $1,117,726,000 after acquiring an additional 199,100 shares during the last quarter. 69.75% of the stock is currently owned by hedge funds and other institutional investors.
In related news, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares in the company, valued at approximately $1,740,918.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the sale, the insider now owns 103,458 shares in the company, valued at $3,827,946. The disclosure for this sale can be found here. Insiders sold a total of 29,450 shares of company stock worth $1,065,220 over the last 90 days. 0.06% of the stock is currently owned by company insiders.
Shares of Pfizer Inc. (PFE) opened at $36.22 on Tuesday. Pfizer Inc. has a 52 week low of $30.90 and a 52 week high of $37.35. The stock has a market capitalization of $215,896.81, a PE ratio of 22.36, a P/E/G ratio of 2.56 and a beta of 1.01. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. During the same period in the previous year, the business posted $0.61 EPS. The firm’s quarterly revenue was up .9% compared to the same quarter last year. equities analysts anticipate that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.
Pfizer announced that its Board of Directors has initiated a share buyback plan on Monday, December 18th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its stock is undervalued.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be paid a $0.34 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 dividend on an annualized basis and a yield of 3.75%. The ex-dividend date of this dividend is Thursday, February 1st. Pfizer’s payout ratio is currently 79.01%.
ILLEGAL ACTIVITY WARNING: “Pfizer Inc. (PFE) Holdings Boosted by Hanson & Doremus Investment Management” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.com-unik.info/2018/01/02/pfizer-inc-pfe-holdings-boosted-by-hanson-doremus-investment-management.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.